KCI Biotech and its wholly-owned subsidiary, KMQ Biotech and KAL Biotech, and the veterinary medicine/pet drug research platform provide comprehensive preclinical drug development services for global veterinary and pet drug enterprises and research institutions.The company owns 17600㎡ of AAALAC-accredited state-of-the-art laboratory animal facilities in Suzhou and Nantong, as well as a 22400㎡ international advanced-level Beagle breeding center, which can meet the needs of various types of preclinical research. There are over 100 types of related animal disease models. The company also has the BSL2/ABSL2 experimental platforms for the development of infectious disease drugs. Meanwhile, the company provides pathology, toxicology, pharmacokinetics, cell and molecular biology, and medical imaging studies.span>